Cite
HARVARD Citation
Gribben, J. et al. (n.d.). AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO. Hematological oncology. pp. 227-229. [Online].